Cargando…
Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab
Cancer genomics and translational medicine rely on the molecular profiling of patient's tumor obtained during surgery or biopsy. Alternatively, blood is a less invasive source of tumor DNA shed, amongst other ways, as cell-free DNA (cfDNA). Highly-sensitive assays capable to detect cancer genet...
Autores principales: | Toledo, Rodrigo A., Cubillo, Antonio, Vega, Estela, Garralda, Elena, Alvarez, Rafael, de la Varga, Lisardo U., Pascual, Jesús R., Sánchez, Gema, Sarno, Francesca, Prieto, Susana H., Perea, Sofía, Lopéz-Casas, Pedro P., López-Ríos, Fernando, Hidalgo, Manuel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471055/ https://www.ncbi.nlm.nih.gov/pubmed/27852040 http://dx.doi.org/10.18632/oncotarget.13311 |
Ejemplares similares
-
Maintenance Therapy With Cetuximab After FOLFIRI Plus Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial
por: Boige, Valérie, et al.
Publicado: (2023) -
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3
por: Fischer, Laura E., et al.
Publicado: (2022) -
Cost-Effectiveness Analysis of First-Line FOLFIRI Combined With
Cetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided Metastatic
Colorectal Cancer
por: Han, Jiaqi, et al.
Publicado: (2020) -
Amphiregulin can predict treatment resistance to palliative first-line cetuximab plus FOLFIRI chemotherapy in patients with RAS wild-type metastatic colorectal cancer
por: Kim, Sang-A, et al.
Publicado: (2021) -
Folfiri-Aflibercept vs. Folfiri-Bevacizumab as Second Line Treatment of RAS Mutated Metastatic Colorectal Cancer in Real Practice
por: Ottaiano, Alessandro, et al.
Publicado: (2019)